Therapy Detail

Therapy Name Docetaxel + Cyclophosphamide
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cyclophosphamide Cytoxan CPM Chemotherapy - Alkylating 14 Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Docetaxel Taxotere Docetaxel anhydrous|Docefrez Antimicrotubule Agent 11 Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01275677 Phase III Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Docetaxel + Cyclophosphamide Docetaxel + Cyclophosphamide + Trastuzumab Paclitaxel + Doxorubicin + Cyclophosphamide Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT01779050 Phase II Trastuzumab Docetaxel Epirubicin + Cyclophosphamide Paclitaxel Fluorouracil + Epirubicin + Cyclophosphamide Docetaxel + Carboplatin Docetaxel + Cyclophosphamide Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Active, not recruiting
NCT01501487 FDA approved Docetaxel + Doxorubicin + Cyclophosphamide Fluorouracil + Epirubicin + Cyclophosphamide Paclitaxel Pegfilgrastim Docetaxel + Cyclophosphamide Doxorubicin + Cyclophosphamide Trastuzumab + Docetaxel + Carboplatin Pertuzumab + Trastuzumab + Docetaxel MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed